Intuitive Surgical Inc (ISRG)
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
- Symbol
- ISRG
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $142.05B
- 52 week range
- 328.57 - 603.88
Valuation
- Share price
- $401.24 (close of 2026-10-01)
- P/E (TTM)
- 45.46x
- Price to book
- 7.76x
- Price to free cash flow
- 44.08x
- Enterprise value
- $139.29B
- Book value per share
- $51.70
Price performance
| Period | Change |
|---|---|
| 1 day | -1.33% |
| 5 days | +0.43% |
| 1 month | +8.66% |
| 3 months | -0.28% |
| 6 months | -13.61% |
| Year to date | -29.15% |
| 1 year | -8.40% |
| 3 years | +37.28% |
| 5 years | +19.25% |
| 10 years | +398.19% |
| All time | +19665.51% |
Members of Congress who disclosed ISRG trades
Josh Gottheimer · Gilbert Ray Cisneros · Lisa McClain · Jefferson Shreve · Bruce Westerman · Markwayne Mullin · Alan Armstrong · Julie Johnson
Super investors holding ISRG
Polen Capital Mgmt (Polen Capital Management LLC)
Profitability and growth
- Return on equity
- 15.92%
- Return on invested capital
- 17.03%
- Return on assets
- 13.96%
- Return on capital employed
- 15.96%
- Gross margin
- 66.00%
- Net margin
- 28.38%
- EBITDA margin
- 35.23%
- Revenue growth
- 20.51%
- Net income growth
- 22.97%
- Free cash flow growth
- 91.03%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 2.27%
- Current ratio
- 4.96x
- Net debt to EBITDA
- -0.65x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $10.06B
- Cost of revenue
- $3.42B
- Gross profit
- $6.64B
- EBITDA
- $3.55B
- Net income
- $2.86B
- Earnings per share
- $8.00
- Research and development
- $1.31B
- Shares outstanding
- 356.90M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $10.06B | $6.64B | $2.86B | $8.00 |
| 2024-12-31 | $8.35B | $5.63B | $2.32B | $6.54 |
| 2023-12-31 | $7.12B | $4.73B | $1.80B | $5.12 |
| 2022-12-31 | $6.22B | $4.20B | $1.32B | $3.72 |
| 2021-12-31 | $5.71B | $3.96B | $1.70B | $4.79 |
| 2020-12-31 | $4.36B | $2.86B | $1.06B | $3.02 |
| 2019-12-31 | $4.48B | $3.11B | $1.38B | $3.98 |
| 2018-12-31 | $3.72B | $2.60B | $1.13B | $3.31 |
| 2017-12-31 | $3.14B | $2.20B | $670.90M | $2.00 |
| 2016-12-31 | $2.71B | $1.89B | $738.30M | $2.14 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 66.00% | 28.38% | 15.92% | 17.03% |
| 2024-12-31 | 67.46% | 27.81% | 14.05% | 13.74% |
| 2023-12-31 | 66.39% | 25.24% | 13.42% | 15.14% |
| 2022-12-31 | 67.44% | 21.25% | 11.90% | 13.66% |
| 2021-12-31 | 69.32% | 29.85% | 14.26% | 15.43% |
| 2020-12-31 | 65.65% | 24.33% | 10.87% | 11.07% |
| 2019-12-31 | 69.45% | 30.80% | 16.65% | 17.43% |
| 2018-12-31 | 69.92% | 30.29% | 16.87% | 17.92% |
| 2017-12-31 | 70.17% | 21.38% | 14.03% | 15.22% |
| 2016-12-31 | 69.94% | 27.28% | 12.68% | 14.69% |
Cash and debt by year
| Period end | Cash |
|---|---|
| 2025-12-31 | $3.37B |
| 2024-12-31 | $2.03B |
| 2023-12-31 | $2.75B |
| 2022-12-31 | $1.58B |
| 2021-12-31 | $1.29B |
| 2020-12-31 | $1.62B |
| 2019-12-31 | $1.17B |
| 2018-12-31 | $857.90M |
| 2017-12-31 | $648.20M |
| 2016-12-31 | $1.04B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $2.49B | $788.20M |
| 2024-12-31 | $1.30B | $676.80M |
| 2023-12-31 | $749.60M | $592.80M |
| 2022-12-31 | $958.40M | $513.20M |
| 2021-12-31 | $1.75B | $449.20M |
| 2020-12-31 | $1.14B | $395.40M |
| 2019-12-31 | $1.17B | $335.80M |
| 2018-12-31 | $982.20M | $261.20M |
| 2017-12-31 | $953.20M | $209.10M |
| 2016-12-31 | $1.03B | $177.60M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-20
- Consensus EPS estimate
- $2.13
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-07-16 | Jun/2026 | $2.02 |
| 2026-04-21 | - | - |
| 2026-01-22 | - | - |
| 2025-10-21 | - | - |
| 2025-07-22 | - | - |
| 2025-04-22 | - | - |
| 2025-01-23 | - | - |
| 2024-10-17 | - | - |
Filings and sources
- Company website
- intuitive.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · Alcon Inc (ALC) · Medline Inc. (MDLN) · Henry Schein Inc (HSIC) · Cardinal Health Inc (CAH) · Cencora, Inc. (COR) · McKesson Corp (MCK)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades